Genprex, Inc. 8-K

What Happened

• On June 22, 2026, Genprex, Inc. announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering the use of REQORSA® Gene Therapy (quaratusugene ozeplasmid) in combination with PD‑1 or PD‑L1 antibodies to treat non‑small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
• The allowance expands Genprex’s existing patent coverage for these combinations, which have previously been granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore, Europe, Korea, Australia and Israel. The company says this protection is relevant to combination therapies being evaluated in its Acclaim‑3 clinical trial.

Key Details

• Date filed/announced: June 22, 2026 (press release disclosed via Form 8‑K).
• Patent scope: REQORSA combined with PD‑1 or PD‑L1 antibodies for NSCLC and SCLC (Notice of Allowance from Canadian IP Office).
• Geographic coverage already secured: U.S., Japan, Mexico, Russia, Chile, China, Singapore, Europe, Korea, Australia, Israel.
• The filing reiterates forward‑looking statement cautions and notes clinical, regulatory, intellectual property and financing risks.

Why It Matters

• Strengthening IP in Canada adds territorial protection for Genprex’s cancer combination approach and supports the commercial and clinical strategy for REQORSA, particularly as the company advances the Acclaim‑3 trial.
• For investors, the allowance is an intellectual property milestone but not a regulatory or clinical approval; it does not guarantee commercial success or reimbursement. Material risks remain (clinical outcomes, regulatory approvals, manufacturing, financing), and the company emphasizes forward‑looking uncertainty.